Arcutis Biotherapeutics Inc.(ARQT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARQT Arcutis Biotherapeutics Inc.

盘前交易 12-19 05:08:00 EST

27.78

-0.56

-1.98%

最高28.90	最低27.55	成交量192.63万
今开28.54	昨收28.34	日振幅4.78%
总市值34.03亿	流通市值24.51亿	总股本1.22亿
成交额5,377万	换手率2.18%	流通股本8,824万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARQT","market":"US","secType":"STK","nameCN":"Arcutis Biotherapeutics Inc.","latestPrice":27.78,"timestamp":1766091600000,"preClose":28.34,"halted":0,"volume":1926342,"delay":0,"floatShares":88242300,"shares":122492192,"eps":-0.350649,"marketStatus":"盘前交易","change":-0.56,"latestTime":"12-19 05:08:00 EST","open":28.54,"high":28.9,"low":27.545,"amount":53771421.297132,"amplitude":0.047812,"askPrice":29.42,"askSize":6,"bidPrice":27.79,"bidSize":114,"shortable":3,"etf":0,"ttmEps":-0.350649,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766154600000},"marketStatusCode":1,"adr":0,"listingDate":1580446800000,"exchange":"NASDAQ","adjPreClose":27.78,"postHourTrading":{"tag":"盘后","latestPrice":27.77,"preClose":27.78,"latestTime":"19:40 EST","volume":141553,"amount":3932340.4281,"timestamp":1766104854731},"volumeRatio":0.8273251246305332,"impliedVol":0.646,"impliedVolPercentile":0.3614},"requestUrl":"/m/hq/s/ARQT","defaultTab":"news","newsList":[{"id":"1183383189","title":"Arcutis加强董事会 新任命Amit Munshi并致敬退休的Bhaskar Chaudhuri","url":"https://stock-news.laohu8.com/highlight/detail?id=1183383189","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183383189?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:00","pubTimestamp":1765227610,"startTime":"0","endTime":"0","summary":"Arcutis加强董事会 新任命Amit Munshi并致敬退休的Bhaskar Chaudhuri","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"1136817101","title":"Arcutis Canada宣布健康加拿大批准ZORYVE泡沫0.3%用于12岁及以上成人和青少年的头皮和身体银屑病","url":"https://stock-news.laohu8.com/highlight/detail?id=1136817101","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136817101?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:39","pubTimestamp":1763573982,"startTime":"0","endTime":"0","summary":"11月13日（路透社）- Arcutis Biotherapeutics Inc.（以下简称“Arcutis Canada”）宣布，健康加拿大已批准ZORYVE泡沫0.3%用于12岁及以上成人和青少年的头皮和身体银屑病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"1189507756","title":"Arcutis Biotherapeutics公布根据纳斯达克上市规则5635(C)(4)的诱导授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1189507756","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189507756?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:12","pubTimestamp":1763572339,"startTime":"0","endTime":"0","summary":"11月8日 - Arcutis Biotherapeutics Inc.宣布根据纳斯达克上市规则5635(C)(4)进行诱导授予。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"1154987264","title":"FDA 接受 Arcutis 的 Zoryve®（Roflumilast）0.3% 乳膏的补充新药申请，以治疗 2 至 5 岁儿童的斑块状银屑病","url":"https://stock-news.laohu8.com/highlight/detail?id=1154987264","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154987264?lang=zh_cn&edition=full","pubTime":"2025-11-17 21:02","pubTimestamp":1763384535,"startTime":"0","endTime":"0","summary":"FDA 接受 Arcutis 的 Zoryve®（Roflumilast）0.3% 乳膏的补充新药申请，以治疗 2 至 5 岁儿童的斑块状银屑病","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2583868465","title":"Arcutis Biotherapeutics, Inc.盘中异动 急速拉升5.03%报24.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583868465","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583868465?lang=zh_cn&edition=full","pubTime":"2025-11-15 00:35","pubTimestamp":1763138124,"startTime":"0","endTime":"0","summary":"北京时间2025年11月15日00时35分，Arcutis Biotherapeutics, Inc.股票出现异动，股价急速拉升5.03%。截至发稿，该股报24.01美元/股，成交量66.4281万股，换手率0.54%，振幅7.70%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.22%。其相关个股中，Cidara Therapeutics, Inc.、Cypherpunk Technologies Inc.、Invivyd, Inc.涨幅较大，Aspire Biopharma Holdings, Inc.、Cypherpunk Technologies Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为983.18%、256.92%、138.99%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Cypherpunk Technologies Inc.、Hcw Biologics Inc.，振幅分别为101.46%、94.31%、59.44%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115003524a4a20bc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115003524a4a20bc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"1101783693","title":"Arcutis Canada：加拿大卫生部批准Zoryve Foam 0.3%用于12岁及以上成人和青少年的头皮及身体银屑病","url":"https://stock-news.laohu8.com/highlight/detail?id=1101783693","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101783693?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:11","pubTimestamp":1763039479,"startTime":"0","endTime":"0","summary":"Arcutis Canada：加拿大卫生部已批准Zoryve Foam 0.3%用于12岁及以上成人和青少年的头皮及身体银屑病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"1194669288","title":"Arcutis完成在婴儿特应性皮炎治疗中的Integument-Infant II期研究的招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1194669288","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194669288?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:00","pubTimestamp":1763038831,"startTime":"0","endTime":"0","summary":"Arcutis完成了在婴儿特应性皮炎治疗中，评估Zoryve®（Roflumilast）0.05%乳膏的Integument-Infant II期研究的招募。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"1158344345","title":"异动解读 | Arcutis Biotherapeutics盘中大涨5.49%，推出儿童特应性皮炎新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1158344345","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158344345?lang=zh_cn&edition=full","pubTime":"2025-10-30 22:00","pubTimestamp":1761832854,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc.今日盘中大涨5.49%，引起投资者广泛关注。此次股价上涨主要受益于公司宣布推出新药物。Arcutis正式推出Zoryve0.05%乳膏，用于治疗2至5岁儿童的轻度至中度特应性皮炎，这一消息极大地提振了投资者信心。Zoryve0.05%乳膏是一种创新性的治疗方案，专门针对年幼儿童的特应性皮炎问题。特应性皮炎是一种常见的慢性炎症性皮肤病，对儿童的生活质量影响较大。这款新药的推出不仅填补了儿童皮肤病治疗的市场空白，也展示了Arcutis在儿科药物研发领域的实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARQT"],"gpt_icon":0},{"id":"1145999908","title":"Arcutis推出Zoryve®（Roflumilast）0.05%乳膏，治疗2至5岁儿童轻度至中度特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1145999908","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145999908?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:01","pubTimestamp":1761825711,"startTime":"0","endTime":"0","summary":"Arcutis推出Zoryve®（Roflumilast）0.05%乳膏，治疗2至5岁儿童轻度至中度特应性皮炎","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"1110228199","title":"异动解读 | 多家券商上调目标价，Arcutis Biotherapeutics盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110228199","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110228199?lang=zh_cn&edition=full","pubTime":"2025-10-29 22:30","pubTimestamp":1761748218,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics今日盘中大涨5.01%，引发市场关注。截至发稿时，该股报价为28.35美元。这一涨幅主要受到多家券商上调目标价的推动。Arcutis Biotherapeutics是一家专注于开发和商业化创新皮肤病治疗方案的生物制药公司。多家券商上调目标价表明分析师对公司未来业绩增长持乐观态度，这可能与公司在研产品管线的进展有关。投资者对此反应积极，推动股价上涨。不过，具体上涨原因仍需进一步观察公司近期是否有重大利好消息公布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARQT"],"gpt_icon":0},{"id":"1146422757","title":"异动解读 | Arcutis Biotherapeutics发布积极财报及销售指引，夜盘大涨6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146422757","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146422757?lang=zh_cn&edition=full","pubTime":"2025-10-29 08:48","pubTimestamp":1761698910,"startTime":"0","endTime":"0","summary":"生物制药公司Arcutis Biotherapeutics Inc.在周二夜盘交易时段股价大涨6.01%，引发市场广泛关注。这一显著涨幅主要源于公司发布的一系列利好消息。Arcutis在当日盘前公布了2025年第三季度财务业绩，同时宣布了推动可持续增长的战略计划。这些积极消息不仅展示了Arcutis当前的良好经营状况，更重要的是传递出管理层对公司长期发展的信心。这一系列公告无疑增强了市场对Arcutis Biotherapeutics未来增长潜力的信心，成为刺激股价上涨的主要推动力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARQT"],"gpt_icon":1},{"id":"1136958456","title":"异动解读 | Arcutis Biotherapeutics盘中大涨19.83%，财报亮眼且发布2026年销售指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1136958456","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136958456?lang=zh_cn&edition=full","pubTime":"2025-10-28 21:40","pubTimestamp":1761658850,"startTime":"0","endTime":"0","summary":"周二交易时段，生物制药公司Arcutis Biotherapeutics Inc.股价大幅上涨19.83%，引发市场广泛关注。这一显著涨幅主要源于公司发布的一系列积极消息。Arcutis在盘前公布了2025年第三季度财务业绩，同时宣布了推动可持续增长的战略计划。更引人注目的是，Arcutis还首次提供了2026年全年净产品销售的初步指导，预计将达到455万至470万美元。这一前瞻性指引表明公司对其产品市场需求和销售增长持乐观态度，进一步刺激了投资者的买入热情。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARQT"],"gpt_icon":0},{"id":"1112295106","title":"异动解读 | Arcutis生物发布增长战略及财报，盘前大涨8.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112295106","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112295106?lang=zh_cn&edition=full","pubTime":"2025-10-28 20:32","pubTimestamp":1761654761,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc.（ARQT）今日盘前大涨8.45%，引发市场广泛关注。这一显著涨幅主要源于公司近期发布的一系列积极消息。\n\n公司在盘前公布了推动可持续增长的战略，同时发布了2025年第三季度财务业绩。这些信息显示出公司在运营和财务方面取得了积极进展，增强了投资者对其未来发展前景的信心。\n\n此外，Arcutis还提供了2026年全年净产品销售的初步指导，预计将达到455万至470万美元。这一前瞻性指引表明公司对其产品市场需求和销售增长持乐观态度，进一步刺激了投资者的买入热情。这些因素共同推动了Arcutis股价在盘前交易中的显著上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARQT"],"gpt_icon":0},{"id":"1161778412","title":"Arcutis Biotherapeutics - 提供2026年全年净产品销售初步指导455万至470万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161778412","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161778412?lang=zh_cn&edition=full","pubTime":"2025-10-28 20:31","pubTimestamp":1761654671,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics - 提供2026年全年净产品销售初步指导455万至470万美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"1198506713","title":"Arcutis公布推动可持续增长的战略，并发布2025年第三季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1198506713","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198506713?lang=zh_cn&edition=full","pubTime":"2025-10-28 20:31","pubTimestamp":1761654669,"startTime":"0","endTime":"0","summary":"Arcutis公布推动可持续增长的战略，并发布2025年第三季度财务业绩","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2576314010","title":"Arcutis Biotherapeutics, Inc.盘中异动 下午盘快速跳水5.05%报20.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576314010","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576314010?lang=zh_cn&edition=full","pubTime":"2025-10-17 02:49","pubTimestamp":1760640578,"startTime":"0","endTime":"0","summary":"北京时间2025年10月17日02时49分，Arcutis Biotherapeutics, Inc.股票出现异动，股价快速下跌5.05%。截至发稿，该股报20.54美元/股，成交量94.45万股，换手率0.79%，振幅5.96%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.51%。其相关个股中，Praxis Precision Medicines, Inc.、冠科美博、Dermata Therapeutics Inc C/Wts 涨幅较大，Theriva Biologics, Inc.、Whitehawk Therapeutics, Inc.、Genprex, Inc.较为活跃，换手率分别为349.39%、195.81%、120.29%，振幅较大的相关个股有Praxis Precision Medicines, Inc.、冠科美博、Whitehawk Therapeutics, Inc.，振幅分别为83.50%、77.02%、62.85%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101702493997324de1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101702493997324de1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"1122676464","title":"FDA批准Arcutis Biotherapeutics Inc.的Zoryve®（罗氟司特）0.05%乳膏用于治疗2至5岁儿童特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1122676464","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122676464?lang=zh_cn&edition=full","pubTime":"2025-10-06 20:01","pubTimestamp":1759752096,"startTime":"0","endTime":"0","summary":"FDA批准Arcutis Biotherapeutics Inc.的Zoryve®（罗氟司特）0.05%乳膏用于治疗2至5岁儿童特应性皮炎","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"1121367392","title":"Arcutis就Zoryve®（罗氟司特）0.3%乳膏提交补充新药申请，以扩大适应症用于治疗2至5岁儿童的斑块状银屑病","url":"https://stock-news.laohu8.com/highlight/detail?id=1121367392","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121367392?lang=zh_cn&edition=full","pubTime":"2025-09-03 23:44","pubTimestamp":1756914255,"startTime":"0","endTime":"0","summary":"Arcutis就Zoryve®（罗氟司特）0.3%乳膏提交补充新药申请，以扩大适应症用于治疗2至5岁儿童的斑块状银屑病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"1102713602","title":"Palvella Therapeutics任命资深科学家兼生物制药高管David W. Osborne博士为首席创新官，进一步充实领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1102713602","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102713602?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:30","pubTimestamp":1756899025,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布任命经验丰富的科学家兼生物制药行业高管David W. Osborne博士担任首席创新官，以此举措进一步加强公司领导层实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","ARQT","BK4139"],"gpt_icon":0},{"id":"2558662746","title":"Arcutis Biotherapeutics, Inc.盘中异动 下午盘急速下挫5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558662746","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558662746?lang=zh_cn&edition=full","pubTime":"2025-08-12 02:24","pubTimestamp":1754936679,"startTime":"0","endTime":"0","summary":"北京时间2025年08月12日02时24分，Arcutis Biotherapeutics, Inc.股票出现波动，股价大幅下跌5.01%。Arcutis Biotherapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.34%。其相关个股中，Equillium, Inc.、Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.涨幅较大，Entero Therapeutics Inc.、Equillium, Inc.、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为6120.24%、634.71%、463.09%，振幅较大的相关个股有Equillium, Inc.、Entero Therapeutics Inc.、Jyong Biotech Ltd.，振幅分别为84.05%、74.27%、62.69%。Arcutis Biotherapeutics, Inc.公司简介：Arcutis Biotherapeutics Inc 是一家医学皮肤科公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812022440a6e00b40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812022440a6e00b40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARQT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcutis.com","stockEarnings":[{"period":"1week","weight":-0.0573},{"period":"1month","weight":0.0183},{"period":"3month","weight":0.5984},{"period":"6month","weight":1.0101},{"period":"1year","weight":1.0731},{"period":"ytd","weight":0.9943}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arcutis Biotherapeutics, Inc.前身是根据特拉华州法律于2016年6月成立的，名称为Arcutis，Inc.，后将名称更改为Arcutis Biotherapeutics，Inc.。该公司是一家后期生物制药公司，致力于针对医疗需求未得到满足的皮肤病开发和商业化治疗。该公司目前的产品组合包括局部治疗，具有潜在的潜力，可以解决免疫介导的皮肤病和疾病或免疫皮肤病。该公司的策略是针对皮肤病学中经过验证的生物学目标识别和开发治疗方法，以提供差异化的临床特征，从而解决现有疗法在目标适应症方面的主要缺点。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.117216},{"month":2,"riseRate":0.833333,"avgChangeRate":0.23515},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027279},{"month":4,"riseRate":0.5,"avgChangeRate":0.042439},{"month":5,"riseRate":0.5,"avgChangeRate":-0.104728},{"month":6,"riseRate":0.833333,"avgChangeRate":0.06903},{"month":7,"riseRate":0.666667,"avgChangeRate":0.023968},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019179},{"month":9,"riseRate":0.5,"avgChangeRate":-0.050429},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.153349},{"month":11,"riseRate":0.5,"avgChangeRate":0.146122},{"month":12,"riseRate":0.666667,"avgChangeRate":0.14632}],"exchange":"NASDAQ","name":"Arcutis Biotherapeutics Inc.","nameEN":"Arcutis Biotherapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcutis Biotherapeutics Inc.(ARQT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arcutis Biotherapeutics Inc.(ARQT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arcutis Biotherapeutics Inc.,ARQT,Arcutis Biotherapeutics Inc.股票,Arcutis Biotherapeutics Inc.股票老虎,Arcutis Biotherapeutics Inc.股票老虎国际,Arcutis Biotherapeutics Inc.行情,Arcutis Biotherapeutics Inc.股票行情,Arcutis Biotherapeutics Inc.股价,Arcutis Biotherapeutics Inc.股市,Arcutis Biotherapeutics Inc.股票价格,Arcutis Biotherapeutics Inc.股票交易,Arcutis Biotherapeutics Inc.股票购买,Arcutis Biotherapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcutis Biotherapeutics Inc.(ARQT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arcutis Biotherapeutics Inc.(ARQT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}